WINTON GROUP Ltd Purchases New Position in NeoGenomics, Inc. $NEO

WINTON GROUP Ltd acquired a new position in shares of NeoGenomics, Inc. (NASDAQ:NEO) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm acquired 63,379 shares of the medical research company’s stock, valued at approximately $925,000.

A number of other institutional investors and hedge funds have also bought and sold shares of NEO. Caitong International Asset Management Co. Ltd lifted its holdings in shares of NeoGenomics by 110.2% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 2,968 shares of the medical research company’s stock worth $35,000 after buying an additional 1,556 shares during the period. Kestra Advisory Services LLC purchased a new position in shares of NeoGenomics during the fourth quarter valued at $39,000. Smartleaf Asset Management LLC raised its holdings in shares of NeoGenomics by 77.7% in the fourth quarter. Smartleaf Asset Management LLC now owns 3,466 shares of the medical research company’s stock valued at $42,000 after acquiring an additional 1,515 shares in the last quarter. Allworth Financial LP raised its holdings in shares of NeoGenomics by 110.4% in the second quarter. Allworth Financial LP now owns 4,132 shares of the medical research company’s stock valued at $60,000 after acquiring an additional 2,168 shares in the last quarter. Finally, Headlands Technologies LLC purchased a new stake in NeoGenomics in the second quarter worth about $32,000. 98.50% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the stock. Weiss Ratings upgraded shares of NeoGenomics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 14th. TD Cowen restated a “buy” rating on shares of NeoGenomics in a report on Wednesday, July 15th. Craig Hallum reaffirmed a “buy” rating and issued a $19.00 price target on shares of NeoGenomics in a research report on Wednesday, July 29th. Needham & Company LLC increased their price objective on shares of NeoGenomics from $15.00 to $19.00 and gave the company a “buy” rating in a research note on Wednesday, July 29th. Finally, Wall Street Zen raised shares of NeoGenomics from a “hold” rating to a “buy” rating in a report on Saturday, June 27th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $17.67.

NeoGenomics Price Performance

Shares of NEO opened at $17.32 on Monday. The company has a 50 day moving average of $15.91 and a two-hundred day moving average of $11.76. The company has a quick ratio of 3.35, a current ratio of 3.60 and a debt-to-equity ratio of 0.48. NeoGenomics, Inc. has a twelve month low of $7.07 and a twelve month high of $19.76. The company has a market cap of $2.23 billion, a price-to-earnings ratio of -43.30 and a beta of 1.75.

NeoGenomics (NASDAQ:NEO) last posted its quarterly earnings data on Tuesday, July 28th. The medical research company reported $0.05 earnings per share for the quarter, topping analysts’ consensus estimates of $0.03 by $0.02. The firm had revenue of $201.66 million during the quarter, compared to analysts’ expectations of $196.93 million. NeoGenomics had a negative return on equity of 1.99% and a negative net margin of 6.77%.The business’s quarterly revenue was up 11.2% on a year-over-year basis. During the same quarter last year, the firm earned $0.03 EPS. As a group, analysts predict that NeoGenomics, Inc. will post -0.09 earnings per share for the current fiscal year.

About NeoGenomics

NeoGenomics, Inc is a provider of cancer-focused diagnostic testing and contract research services. The company operates clinical laboratories that support physicians, hospitals and other healthcare organizations with information used to help diagnose, classify and monitor cancer.

Its testing services include anatomic pathology, immunohistochemistry, flow cytometry, cytogenetics, fluorescence in situ hybridization, molecular testing and next-generation sequencing. NeoGenomics also provides biopharmaceutical companies with clinical trial testing, central laboratory services, biomarker development and other research services intended to support the development of oncology therapies and companion diagnostics.

Founded in 1999, NeoGenomics serves healthcare providers and pharmaceutical and biotechnology customers primarily in the United States, with additional capabilities supporting international clinical research programs.